ArticleInfectious diseases and therapy2023
Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a Systematic Review and Modelling Study.
Article in Infectious diseases and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 5 syntheses or guidelines pooled it, 137 citations in OpenAlex.
- Burden of Respiratory Syncytial Virus Infection in Immunocompromised Adults: A Systematic Review of the Evidence From High-Income Countries.Infectious diseases and therapy · 2026Pooled it
- Estimating the respiratory syncytial virus-associated hospitalisation burden in older adults in European countries: a systematic analysis.BMC medicine · 2025Pooled it
- Burden of Respiratory Syncytial Virus (RSV) Infection Among Adults in Nursing and Care Homes: A Systematic Review.Influenza and other respiratory viruses · 2024Pooled it
- Respiratory syncytial virus disease burden in children and adults from Latin America: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Epidemiology and burden of respiratory syncytial virus in Italian adults: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Immunogenicity and Safety of Co-administration of Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine With 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years: A Randomized, Non-inferiority Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Incidence of respiratory syncytial virus and influenza: A Danish nationwide cohort study.Human vaccines & immunotherapeutics · 2026Article
- Healthcare resource use and costs following RSV-related hospitalizations among US adults aged 50 years and older.Human vaccines & immunotherapeutics · 2026Article
- Bivalent RSVpreF Effectiveness Against Respiratory Syncytial Virus (RSV)-Related Respiratory Disease Hospitalization and Emergency Department Visits Across Three RSV Seasons.Infectious diseases and therapy · 2026Article
- Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Older Adults in the Netherlands.Infectious diseases and therapy · 2026Article
- Early bedside risk stratification using Charlson comorbidity index and NEWS2 in adults hospitalized with respiratory syncytial virus infection: a multicentre cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Viral Pathogen-Specific Severe Acute Respiratory Infections in Hospitalised Adults in Europe: Epidemiological Findings from the id.DRIVE Study 2024-2025.Infectious diseases and therapy · 2026Article
- Article
- Cost-effectiveness of a single dose of the adjuvanted respiratory syncytial virus preFusion protein 3 vaccine over 5 years and its potential public health impact among older adults in Italy.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- AS01Drug safety · 2026Article
- The Clinical and Symptomatic Burden Among Older Adults with Respiratory Syncytial Virus: A Real-World Survey in Five European Countries.Infectious diseases and therapy · 2026Article
- Bivalent RSVpreF effectiveness against RSV-associated hospital or emergency department care over two seasons: a retrospective test-negative case control study.Lancet regional health. Americas · 2026Article
- Long-term Clinical Outcomes After Hospitalization for Acute Respiratory Illness Due to Respiratory Syncytial Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Burden of Respiratory Syncytial Virus Among Older Adults With an Acute Respiratory Infection: A Prospective Study in Six European Countries.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Observational
- A Cross-Country Evaluation of Respiratory Syncytial Virus and Human Metapneumovirus Surveillance Systems: Identifying Gaps and Best Practices for Improved Disease Monitoring.Reviews in medical virology · 2026Review
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 6 countries.
Funding
Abstract
introductionPrevious studies suggest diagnostic testing characteristics (i.e. variations in clinical specimens and diagnostic tests) can contribute to underestimation of RSV disease burden. We aimed to improve the understanding of RSV hospitalisation burden in older adults (aged ≥ 65 years) in high-income countries through adjusting for case under-ascertainment.
methodsWe conducted a systematic review to include data on RSV-associated acute respiratory infection (ARI) hospitalisation burden in older adults in high-income countries. To adjust for case under-ascertainment, we developed a two-step framework that incorporated empirical data on the RSV detection proportion of different clinical specimens and testing approaches as well as their statistical uncertainty. We estimated the unadjusted and adjusted RSV-associated hospitalisation burden through multilevel random-effects meta-analysis. We further explored RSV-associated in-hospital mortality burden.
resultsWe included 12 studies with eligible RSV hospitalisation burden data. We estimated that pooled unadjusted hospitalisation rate was 157 per 100,000 (95% CI 98-252) for adults aged ≥ 65 years; the rate was adjusted to 347 per 100,000 (203-595) after accounting for under-ascertainment. The adjusted rate could be translated into 787,000 (460,000-1,347,000) RSV-associated hospitalisations in high-income countries in 2019, which was about 2.2 times the unadjusted estimate. Stratified analysis by age group showed that the adjusted rate increased with age, from 231 per 100,000 in adults aged 65-74 years to 692 per 100,000 in adults aged > 85 years. The in-hospital case fatality ratio of RSV was 6.1% (3.3-11.0) and the total RSV-associated in-hospital deaths in high-income countries in 2019 could be between 22,000 and 47,000.
conclusionThis study improves the understanding of RSV-associated hospitalisation burden in older adults and shows that the true RSV-associated hospitalisation burden could be 2.2 times what was reported in existing studies. This study has implications for calculating the benefit of interventions to treat and prevent RSV-associated disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.